MedTrace Logo

Individualized Multimodal Hemostasis Evaluation Pyramid (IMHOTEP)

NCT03555383 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 59

Last updated 2020-09-02

No results posted yet for this study

Summary

This study evaluates the hemostatic changes defined as hemostasis reserve capacity (HRC) in the first perioperative 48 hours of bloodless liver transplanted patients.

Conditions

  • Blood Loss, Postoperative
  • Liver Transplant
  • Hemostatic Disorder

Interventions

DIAGNOSTIC_TEST

Coagulation factor levels

The minimal functional hemostasis reserve capacity are defined by triggers as hematocrit: 27%, platelets: 30 G/l, Fibrinogen (FI): 1g/l, FII-FV-FVII-FX: 30%, Antithrombin III: 40%, FXIII: 60% levels. The estimate blood volume methodology is used for to determine the amount of allowable blood loss in volume (ml) that does not require replacement based on current and trigger levels. The individualized pyramid of intervention defined as hemostasis reserve capacity are followed at every studied patient. All measurements and calculations are performed before liver transplantation (T1), at arrival on Intensive Care Unit (T2) and 12-24-48 hours after liver transplantation (T3-4-5).

Sponsors & Collaborators

  • Semmelweis University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-01
Primary Completion
2020-08-01
Completion
2020-08-31

Countries

  • Hungary

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03555383 on ClinicalTrials.gov